Insulet Corp (PODD) Stock Price & Analysis
Insulet Corp (PODD) fell 2.06% to USD 147.48 as of September 8, 2026 at 06:21 UTC, according to Nexqual real-time market data.
PODD last closed at USD 150.58; the session ranged USD 145.42–150.56 on volume of 1,058,435 shares. Market capitalization is $10.23B, with a 52-week range of USD 126.4–354.88 (NMS). Source: Nexqual, September 8, 2026 at 06:21 UTC.
Key Statistics (as of September 8, 2026 at 06:21 UTC)
| Price | USD 147.48 |
|---|---|
| Change | ▼ 2.06% (down) |
| Previous Close | USD 150.58 |
| Open | USD 149.32 |
| Day Range | USD 145.42 – 150.56 |
| 52-Week Range | USD 126.4 – 354.88 |
| Volume | 1,058,435 shares |
| Market Cap | $10.23B |
| Exchange | NMS |
Technical Analysis (PODD)
Nexqual's technical model rates PODD "SELL" based on 1 bullish and 4 bearish signals across 128 daily candles, as of September 8, 2026 at 06:21 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 46.12 (neutral) |
| vs SMA50 | Below (USD 154.32) |
| MACD | -1.5 (negative) |
Analyst Ratings (PODD)
Wall Street analysts rate PODD "None" based on 22 analysts, with a mean price target of USD 171.91 (range USD 144–275), per Nexqual as of September 8, 2026 at 06:21 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 22 |
| Mean Target | USD 171.91 |
| High Target | USD 275 |
| Low Target | USD 144 |
| Buy / Hold / Sell | 15 / 10 / 0 |
Earnings (PODD)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD 1.59 |
| Revenue Estimate | $833.22M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 1.66 vs est 1.45 ▲ beat |
| 2026-03-31 | USD 1.42 vs est 1.19 ▲ beat |
| 2025-12-31 | USD 1.55 vs est 1.46 ▲ beat |
| 2025-09-30 | USD 1.24 vs est 1.15 ▲ beat |
Source: Nexqual, September 8, 2026 at 06:21 UTC.
Financials & Fundamentals (PODD)
| Total Revenue | $3.05B |
|---|---|
| Revenue Growth (YoY) | +23.50% |
| Gross Margin | +71.08% |
| Operating Margin | +16.18% |
| Profit Margin | +12.29% |
| ROE | +26.02% |
| Debt / Equity | 66.69 |
| Current Ratio | 2.49 |
| Total Cash | $534.90M |
| Total Debt | $948.40M |
| Free Cash Flow | $236.90M |
Source: Nexqual, September 8, 2026 at 06:21 UTC.
Financial Health Score (PODD)
Nexqual rates Insulet Corp's overall financial health "Strong" across five dimensions, as of September 8, 2026 at 06:21 UTC.
| Growth | Strong — Revenue +31% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 71%, operating 16% |
| Balance Sheet | Strong — $535M cash vs $948M debt |
| Cash Flow | Solid — FCF $237M, 9% margin |
| Efficiency | Strong — ROE 26%, ROA 9.7% |
Ownership (PODD)
| Insider Ownership | +0.33% |
|---|---|
| Institutional Ownership | +107.32% |
| Shares Outstanding | 69.35M |
| Float | 69.06M |
| Short % of Float | +6.02% |
Source: Nexqual, September 8, 2026 at 06:21 UTC.
Leadership (PODD)
Insulet Corp is led by Ashley A. McEvoy (age 54), CEO, President & Director, per Nexqual as of September 8, 2026 at 06:21 UTC.
| CEO, President & Director | Ashley A. McEvoy (age 54) |
|---|---|
| Executive VP & CFO | Flavia H. Pease (age 52) |
| Executive VP & COO | Eric Benjamin (age 42) |
| Senior Vice President of Global Operations | Prem Singh (age 48) |
| Senior VP & CTO | Amit Guliani |
Major Backers & Investors (PODD)
Notable institutional backers of Insulet Corp include Invesco, AQR Capital Management, LLC, T. Rowe Price, according to Nexqual as of September 8, 2026 at 06:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Invesco | 4.22% |
| AQR Capital Management, LLC | 3.54% |
| T. Rowe Price | 3.33% |
| Baillie Gifford | 2.94% |
| Two Sigma Investments, LP | 2.74% |
| Fidelity | 1.29% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 20.33% |
| BlackRock | 11.02% |
| State Street | 5.84% |
| Geode Capital | 2.89% |
Source: Nexqual, September 8, 2026 at 06:21 UTC.
From Insulet Corp's Latest SEC 10-K Filing (filed 2026-02-18)
Key Strengths & Strategy (as disclosed to the SEC)
- As a medical device manufacturer and distributor, our manufacturing facilities and the facilities of our suppliers are subject to periodic inspection by the FDA, certain corresponding state agencies, and other regulatory bodies. 7 Table of Contents Intellectual Property To maintain a competitive advantage, we believe we must develop and preserve the proprietary aspect of our technologies.
- Our Omnipod platform's unique patented design allows us to provide Pod therapy at a relatively low or no up-front investment, which reduces the risk to third-party payors in the United States.
- We rely on a combination of copyright, patent, trademark, trade secret, and other intellectual property laws, non-disclosure agreements, and other measures to protect our proprietary rights.
- Patents As of December 31, 2025, we had over 1,000 patents in the United States and certain other countries, with expiration dates ranging from 2026 through 2047 and had over 700 patent applications pending.
Partnerships
- Data Management We have partnered with Glooko Inc. ("Glooko") to connect user data with Glooko's comprehensive diabetes data management system (including Diasend in selected regions).
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| DXCM | DexCom, Inc. | USD 87.9 | ▼ 2% |
| TNDM | Tandem Diabetes Care, Inc. | USD 19.9 | ▼ 3.21% |
| PEN | Penumbra, Inc. | USD 322.17 | ▼ 0.2% |
| RMD | ResMed Inc. | USD 228.35 | ▼ 1.09% |
| WST | West Pharmaceutical Services, I | USD 339.97 | ▼ 0.78% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 06:21 UTC. This page is informational and not investment advice.